Biodrugs

Biodrugs is a peer-reviewed journal published by Springer under the Adis imprint since 1997 under the ISSN 1173-8804 and eISSN 1179-190X, covering biologic drugs and biosimilars across their full lifecycle from development to clinical use, with a 2025 Journal Impact Factor of 8.5 and first quartile ranks of 19 of 183 in immunology, 40 of 333 in oncology and 19 of 356 in pharmacology and pharmacy《生物药物》（Biodrugs）是施普林格（Springer）以阿迪斯（Adis）印记自 1997 年起出版的同行评审期刊，刊号 1173-8804、电子刊号 1179-190X，覆盖生物药与生物类似药从开发到临床使用的全生命周期，2025 年影响因子为 8.5，在免疫学类 183 种期刊中列第 19 位、在肿瘤学类 333 种期刊中列第 40 位、在药学与药剂学类 356 种期刊中列第 19 位，均居第一四分位。

Scope

• The journal publishes original research, reviews, systematic reviews and therapeutic outcome analyses on biologic drugs including monoclonal antibodies, fusion proteins, cytokines, growth factors and cell and gene therapies该刊刊载生物药的原创研究、综述、系统综述与治疗结局分析，生物药包括单克隆抗体、融合蛋白、细胞因子、生长因子及细胞与基因治疗。
• It covers biosimilars including their development, analytical and clinical comparability, regulatory and approval pathways, switching and interchangeability, and the real-world evidence and pharmacoeconomic aspects of biosimilar use该刊覆盖生物类似药，包括其开发、分析与临床可比性、监管与审批路径、转换与可互换性，以及生物类似药使用的真实世界证据与药物经济学方面。
• The journal addresses the clinical use of biologics across therapeutic areas including oncology, rheumatology and autoimmune disease, dermatology, gastroenterology, neurology and ophthalmology, with an emphasis on therapeutic outcomes and safety该刊涉及生物药在肿瘤学、风湿病学与自身免疫病、皮肤病学、胃肠病学、神经病学与眼科学等治疗领域的临床使用，侧重治疗结局与安全性。
• It also covers the pharmacoeconomics and quality of life impact of biologic therapies, the regulatory and health technology assessment landscape for biologics and biosimilars, and the market access and pricing of biologic drugs该刊亦覆盖生物治疗的药物经济学与生活质量影响、生物药与生物类似药的监管与卫生技术评估格局，以及生物药的市场准入与定价。
• It operates single-blind peer review and follows the Springer editorial policies on research integrity, data availability and competing interests, with author guidelines published on the journal website该刊实行单盲同行评审，遵循施普林格关于研究诚信、数据可获取性与利益冲突的编辑政策，作者指南在期刊网站公布。
• In the 2025 Journal Citation Reports it ranks 19 of 183 in immunology, 40 of 333 in oncology and 19 of 356 in pharmacology and pharmacy, with five year indicators in the first quartile for all three categories在 2025 年版期刊引证报告中，该刊在免疫学类 183 种期刊中列第 19 位、在肿瘤学类 333 种期刊中列第 40 位、在药学与药剂学类 356 种期刊中列第 19 位，三类五年指标均居第一四分位。

History

• The journal was launched in 1997 by Adis International as a dedicated title for biologic drugs, later becoming part of the Springer portfolio when Springer acquired Adis, and it has since been published under the Adis imprint within Springer该刊于 1997 年由阿迪斯国际（Adis International）创刊，作为生物药的专门期刊，施普林格收购阿迪斯后并入施普林格期刊群，此后以施普林格内的阿迪斯印记出版。
• It has been published bimonthly throughout most of its history, with six issues per volume per year, and it is one of the leading titles dedicated to biologic drugs and biosimilars该刊历史上大部分时间以双月刊形式出版，每年一卷六期，是生物药与生物类似药领域的主要期刊之一。
• The Journal Impact Factor moved from 5.807 in 2021 to 7.744 in 2022, then to 6.9 in 2024 and to 8.5 in 2025, maintaining first quartile standing across its three categories throughout该刊影响因子由 2021 年的 5.807 升至 2022 年的 7.744，再降至 2024 年的 6.9 与 2025 年的 8.5，始终居三类学科第一四分位。
• The journal has progressively expanded its coverage to address biosimilars, real-world evidence, health technology assessment and cell and gene therapies, reflecting the maturation of the biologics field and the growth of the biosimilar market该刊逐步扩展覆盖以纳入生物类似药、真实世界证据、卫生技术评估及细胞与基因治疗，反映生物药领域的成熟与生物类似药市场的增长。
• The publisher carries the journal on Springer Link and the digital object identifier prefix of its articles is 10.1007, shared with other Springer journals出版方将该刊载于施普林格链接平台，其文章的数字对象唯一标识符前缀为（10.1007），与施普林格其他期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an editorial board whose members are drawn from clinical pharmacology, rheumatology, oncology, immunology and health economics across academia, industry and regulatory bodies该刊由一位主编带领，配以由学术界、产业界与监管机构临床药理学、风湿病学、肿瘤学、免疫学与卫生经济学的学者组成的编委会。
• The editorial team includes associate editors responsible for subject areas such as biosimilars, oncology biologics, autoimmune and inflammatory disease, pharmacoeconomics and regulatory affairs, reflecting the breadth of the biologics field编辑团队设有副编辑，分别负责生物类似药、肿瘤生物药、自身免疫与炎症性疾病、药物经济学与监管事务等方向，对应生物药领域的广度。
• Editorial handling follows the Springer editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托施普林格的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is single-blind and the journal maintains the Springer and Adis standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循施普林格与阿迪斯在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at Springer Link and updated as new members join or existing members step down编委名单在施普林格链接期刊页公布，并随成员增减而更新。